Skip to Content
Business Wire

Ikonisys Announces the Installation of the Ikoniscope20 Solution at a US Leading Urology Laboratory

Ikonisys Announces the Installation of the Ikoniscope20 Solution at a US Leading Urology Laboratory

Regulatory News:

Ikonisys SA (Code ISIN: FR00140048X2 / Mnemonic: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully-automated solution for medical diagnostic labs, announces the installation of an Ikoniscope20 digital fluorescence microscope solution at one of the most advanced urology laboratories of the United States, with more than 50 providers delivering state-of-the-art care in several locations.

The new placement is at a leading national healthcare delivery group committed to enhancing access to specialty healthcare and continually improving patient outcomes.

It is one of the most impactful urology organizations in the United States, with a physician network that spans over ten states, with 500+ providers treating more than 700,000 unique patients annually.

The Ikoniscope20 solution will be utilized to automate early bladder cancer detection. Ikonisys delivered a tailor-made diagnostic application developed with the Ikonisys’ rapid development platform.

Manny Iglesias, Sales Director USA of Ikonisys, said: “This is yet another proof of the technological superiority of our solution, chosen by one of the most reputable urology laboratory and part of one of the biggest urology groups of the country. This sale fits perfectly in the commercialization strategy for the United States announced during the IPO of Ikonisys, focusing on important key opinion leaders that could pave the way for further sales.”

About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.

Alessandro Mauri

Olivier Bricaud / Louis-Victor Delouvrier
Investor Relations
Tel.: +33 (0)1 44 71 94 92

Nicolas Merigeau
Media Relations
Tel.:+33 (0)1 44 71 94 98

View source version on